Optonol's flagship product, Ex-Press, is a miniature surgical implant used to lower intra-ocular pressure in patients with glaucoma.

Optonol was founded as a spin-off of Jerusalem-based stent developer Medinol Ltd.

Optonol was acquired by Alcon in December 2009.

A year later, Alcon was acquired by Novartis.